PharmTech Talk

Dec 01, 2016
The House-approved 21st Century Cures legislation supports initiatives for medical research, drug development, and faster approvals, but comes up short on actual appropriations.
Nov 18, 2016
Biopharma proponents argue for FDA resources, Cures legislation, and science-based drug regulation.
Nov 09, 2016
What’s ahead for the healthcare and pharmaceutical industries?
Nov 02, 2016
The biosimilar pathway permits licensure based on less than full clinical data.
Oct 24, 2016
FDA’s new Office of Tissues and Advanced Therapies will oversee a growing range of cellular and genetic products.
Oct 20, 2016
FDA leaders insist that the decision to approve Sarepta’s Exondys (eteplirsen) should not be considered a model for future development of orphan drugs.
Oct 10, 2016
PharmTech's Editorial Director, Rita Peters, addresses the CPhI Pharma Awards' finalists at this year's CPhI Awards Gala.
Oct 05, 2016
Value assessment initiatives are expected to have a major impact on drug use and reimbursement.
Sep 15, 2016
Industry concerns have generated efforts by FDA to streamline the system for designating the lead center to regulate a new combination product.
Sep 12, 2016
Concerns have emerged that continued growth in the biosimilars market could be limited by mounting pressure to push down on prescription drug outlays.
lorem ipsum